Genetic markers: Genes involved in atherosclerosis

Journal of Cardiovascular Risk

Volumn 4, Issue 5, 1997, Pages 333-339

  Marian, Ali J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Coronary artery disease; Genetics; Myocardial infarction; Risk factors

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; ARYLESTERASE; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; DIPEPTIDYL CARBOXYPEPTIDASE; DNA; FIBRINOGEN; FIBRINOGEN RECEPTOR; HOMOCYSTEINE; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ATHEROSCLEROSIS; CHROMOSOME 13Q; CHROMOSOME 17Q; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 3Q; CHROMOSOME 4Q; CHROMOSOME 7Q; CORONARY ARTERY DISEASE; GENE MAPPING; GENETIC MARKER; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ARTERIOSCLEROSIS; ARYLDIALKYLPHOSPHATASE; CHROMOSOME MAPPING; ESTERASES; FIBRINOGEN; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; PEPTIDYL-DIPEPTIDASE A; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0031425355     PISSN: 13506277     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043798-199710000-00003     Document Type: Article

References (75)

1. American Heart Association Heart and Stroke Facts: 1995 Statistical Supplement. Dallas, TX: American Heart Association; 1195.
2. Garg R, Packer M, Pitt B, Yusuf S: Heart Failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol 1993, 22:3A-5A.
3. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
4. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel B: Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986, 256:2835-2838.
5. Castelli WP: The epidemiology of coronary heart disease: the Framingham study. Am J Med 1984, 76:4-12.
6. Wilson PWF: Established risk factors and coronary artery disease: the Framingham study. Am J Hypertens 1994, 7:7S-12S.
7. Hegele RA: Gene-environment interactions in atherosclerosis. Mol Cell Biochem 1992, 113:177-186.
8. Marenberg ME, Risch N, Berkman LF, Floderus B, de-Faire U: Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994, 330:1041-1046. This major study shows that death from CAD in people of younger ages is influenced by genetic factors both in female and male. Utilizing data from 26 years of follow-up, the investigators studied the risk of death from coronary heart disease in pairs of 3298 monozygotic and 5964 dizygotic male twins and 4012 monozygotic and 7730 dizygotic female twins. The results illustrated several points. First, a predisposition to death from CAD was present, and decreased with increasing age. The relative hazard of death was 8.1 for monozygotic twins and 3.8 for dizygotic twins when one /Es twin died of CAD before age 55 years. The relative hazard of death was even greater in women, 15 for monozygotic twins and 2.6 for dizygotic twins, when one >Es twin died of CAD before age 65 years.
9. Chamberlain JC, Galton OJ: Genetic susceptibility to atherosclerosis. Br Med Bull 1990, 46:917-940
10. Hopkins PN, Williams RR, Kuida H, Stults BM, Hunt SC, Barlow GK, et al.: Family history as an independent risk factor for incident coronary artery disease in a high risk cohort in Utah. J Chron Dis 1986, 62:708-713.
11. Jorder LB, Williams RR: Relation between family history of coronary artery disease and coronary risk variables. Am J Cardiol 1988, 62:708-713.
12. The Genome Directory. Nature 1995, 277 (Suppl):175-298.
13. Adams MD, Kerlavage AR, Fleischmann RD, Fuldner RA, Bult CJ, Lee NH, et al.: Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence. The genome directory. Nature 377 (suppl):3-174.
14. Slack J, Evans KA. The increased risk of death from ischemic heart disease in first degree relatives of 121 men and 96 women with ischemic heart disease. J Med Genet 1966, 3:239-257.
15. Berg K: Genetics of coronary artery disease. Prog Med Genet 1983, 5:35-90.
16. Brenn T: Genetic and environmental effects on coronary heart disease risk factors in Northern Norway. The cardiovascular disease study in Flnnmark. Hum Genet 1994, 58:369-379.
17. Fuster V, Badimon L, Badimon J, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992, 326:242-250.
18. Fuster V, Badimon L, Badimon J, Chesebro JH: The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992, 326:310-318.
19. van der Wall AC, Becker AE, van der Loos CM, Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994, 89:36-44.
20. Lander ES, Schork NJ: Genetic dissection of complex traits. Science 1994,265:2037-2048. This is an outstanding review of the genetic approach to identify the genes responsible for complex diseases such as CAD. The authors, who are world-class authorities in this field, describe four major approaches: linkage analysis, allele-sharing methods, association studies and experimental crosses. They describe the methodological approaches, and the strength, limitations and applications of the approaches to biological problems.
21. Lander E, Kruglyak L: Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nature Genet 1995, 11:241-247.
22. Thompson G: Identifying complex disease genes: progress and paradigms. Nature Genet 1994, 8:108-110.
23. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P, et al.: Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994, 330:1629-1633.
24. Field LL, Tobias R, Magnus T: A locus on chromosome 15q26 (IDDM3) produces susceptibility to insulin-dependent diabetes mellitus. Nature Genet 1994, 8:189-194.
25. Davies JL, Kawaguchi Y, Bennet ST, Copeman JB, Cordell HJ, Pritchard LE, et al A genome-wide search for human type-1 diabetes susceptibility genes. Nature 1994, 371:130-136.
26. Griendling KK, Murphy TJ, Wayne Alexander R: Molecular biology of the renin-angiotensin system. Circulation 1993, 87:1816-1828.
27. Mombouli JV, Vanhoutte PM: Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharm Toxicol 1995, 35:679-705.
28. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 (PAI-1) in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995, 95:995-1001.
29. James IM, Dickenson EJ, Burgoyne W, Jeremy JY, Barrados MA, Mikhalidis DP, et al.: Treatment of hypertension with captopril: preservation of regional blood flow and reduced platelet aggregation. J Hum Hypertens 1988, 2:21-25.
30. Pieruzzi F, Abassi ZA, Keiser HR: Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure. Circulation 1995, 92:3105-3112.
31. Passier RC, Smits JF, Weruyten MJ, Studer R, Drexler H, Daemen MJ: Activation of angiotensin-converting enzyme expression in infarct zone following myocardial infarction. Am J Physiol 1995, 269:H1268-1276.
32. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell B: Increased rat cardiac angiotensin converting enzyme activity and mRNA levels in pressure overload left ventricular hypertrophy. Circulation 1993, 87:1328-1339. ACE is an important enzyme that converts angiotensin I to angiotensin II. The latter is a mitogenic as well as a trophic hormone. The role of ACE in modulating cardiac growth is supported by demonstration of expression of ACE in the myocardium and its upregulation during pressure overload induced cardiac hypertrophy as demonstrated in this study.
33. Hokimoto S, Yasue H, Fujimoto K, Yamamoto H, Nakao K, Kaikita K, et al.: Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation 1996, 94:1513-1518.
34. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, et al.: Evidence, from combined segregation and linkage analysis that a variant of the angiotensin l-converting enzyme (ACE) gene controls plasma angiotensin-1 converting enzyme levels. Am J Hum Genet 1992, 51:197-205.
35. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corval P, Soubrier F: An insertion/deletion polymorphism in the angiotensin l-converting enzyme gene accounting for half of the variance of serum enzyme levels. J Clin Invest 1990, 86:1343-1346.
36. Danser AHJ, Schalekamp MADH, Bax WA, van der Brink AM, Saxena PR, Riegger GAJ, et al.: Angiotensin-converting enzyme in the human heart: effect of the deletion/insertion polymorphism. Circulation 1995, 92:1387-1388.
37. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, et al.: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992, 359:641-644. This is the first study to implicate the ACE DD genotype as a risk factor for myocardial infarction. ACE I/D polymorphism is a major determinant of the plasma level of ACE, accounting for approximately 50% of its variance. Individuals with the DD genotype have higher plasma ACE level than those with ID or II genotype. Cambien and his colleagues show that DD genotype was more common in patients with Ml than in controls, especially among patients with low body mass index and low plasma level of ApoB.
38. Beohar N, Prather A, Yu Q-T, Raizner AE, Kleiman NS, Robert R, et al.: Angiotensin converting enzyme genotype DD is a risk factor for coronary artery disease. J Invest Med 1995, 43:275-280.
39. Samani NJ, Thompson JR, O’Toole L, Channer K, Woods KL: A metaanalysis of the association of the deletion allele of the angiotensinconverting enzyme gene with myocardial infarction. Circulation 1996, 94:708-712.
40. Yusuf S, Pepine CJ, Gares C, Pouleur H, Salem D, Kostis J, et al.: Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992, 340:1173-1178.
41. The SOLVD investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
42. Sharpe N: The effects of angiotensin-1 converting enzyme inhibition on progression of atherosclerosis. J Cardiovasc Pharmacol 1993, 22 (suppl 9):S9-S12.
43. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW: Homeostatic factors and the risk of Ml or sudden death in patients with angina pectoris. N Engl J Med 1995, 332:635-641. Acute coronary syndomes such as myocardial infarction are, in general, caused by thrombus formation at the site of injured endothelium. In this study, ECAT investigators report that plasma level of homeostatic factors such as fibrinogen, von Willebrand factor antigen, and tPA antigen are independent predictors of subsequent acute coronary syndromes. In addition, they show that low concentration of fibrinogen is protective against acute coronary syndromes regardless of serum cholesterol level.
44. Kanell WB, Wolf PA, Castelli WP, D’Agostino RB: Fibrinogen and risk of cardiovascular disease: The Framingham Study. JAMA 1987, 258:1183-1186.
45. Henry I, Uzan G, Weil D, Nicolas H, Kaplan JC, Marguerie C, et al.: The genes coding for Aα-, Bβ-, and γ-chains of fibrinogen map to 4q2. Am J Hum Genet 1984, 36:760-768.
46. Humphries SE, Cook M, Dubovitz M, Stirling Y, Meade TW: Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987, i:1452-1455.
47. Scarabin P-Y, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, et al.: Genetic variation at the (3-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of Ml: The ECTIM study. Arterioscler Thromb 1993, 13:886-891.
48. Green F, Hamsten A, Blomback M, Humphries S: The role of (3-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of MI and healthy controls from Sweden. Thromb Haemost 1993, 70:915-920.
49. Yu Q-T, Safavi F, Roberts R, Marian AJ: A potent genetic risk factor for coronary artery disease. J Invest Med 1996, 44:154-159.
50. Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, et al.: β fibrinogen gene polymorphism are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction (The ECTIM Study). Circulation 1996, 93:440-449.
51. Mackness Ml, Arrol S, Durrington PN: Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991, b:152-154.
52. McElveen J, Mackness Ml, Colley CM, Peard T, Warner S, Walker CH: Distribution of paraoxon hydrolysing activity in the serum of patients after myocardial infarction. Clin Chem 1986, 32:671-673.
53. Furlong CE, Richter RJ, Seidel SJ, Motulsky A: Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet 1988, 43:230-238.
54. Humbert R, Adler DA, Disteche CK, Hassett C, Omiecinski CJ, Furlong CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet 1993, 3:73-76. Paraoxonase is a HDL associated protein with no known physiologic substrate in humans. However, increasing evidence suggest that paraoxonase plays a significant role in atherosclerosis, most likely through its influence on oxidation of LDL. There is a 10-40 fold variation in plasma paraoxonase level among individuals. There is a genetic basis for such, as large inter-individual variations were shown to be the result of a polymorphism in position 91 of the enzyme where an arginine substitutes for glutamine. Arginine at position 92 confers higher paraoxonase activity than glutamine. This polymorphism has been implicated as a genetic marker for atherosclerosis.
55. Adkins S, Gan KN, Mody M, LaDu BN: Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993, 52: 598-608.
56. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, et al.: Gln-Arg192 polymorphism of paraoxonase and coronary artery disease in type 2 diabetes. Lancet 1995, 346:869-872.
57. Serrato M, Marian A: A Variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995, 96:3005-3008.
58. A2: an inherited platelet risk factor for early coronary thrombotic events [abstract]. Circulation 1995, 92:1-30.
59. Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein llb/llla receptors in cardiovascular medicine. N Engl J Med 1995, 332:1553-1559. Platelet glycoprotein llb/llla receptors play a major role in platelet adhesion and aggregation and also, therefore, in the thrombotic complications of atherosclerosis. In this review the authors summarize the state of the art knowledge about the biology of llb/llla receptors, their role in cardiovascular medicine and the development and use of llb/llla inhibitors for treatment of myocardial infarction and unstable angina.
60. Rosa J-P, Bray PF, Gayet O, Johnston Gl, Cook RG, Jackson KW, et al.: Cloning of glycoprotein ilia cDNA from human erythroleukemia cells and localization of the gene to chromosome 17. Blood 1988, 72:593-600.
61. 3 (glycoprotein α/-llia) in a variant of Glanzmann thrombasthenia. Proc Natl Acad Sci USA 1992, 89:10169-10173.
62. 33 amino acid polymorphism in membrane glycoprotein Ilia, and are distinguishable by DNA typing. J Clin Invest 1989, 83:1778-1781.
63. Marian AJ, Brugada R, Kleiman NS: Platelet glycoprotein Ilia PIA polymorphism and myocardial infarction. N Engl J Med 1996, 335:1071-1072.
64. Mayer EL, Jacobsen DW, Robinson K: Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996, 27:517-527. Increased plasma level of homocysteine is a known factor for atherosclerosis. A number of factors influence plasma level of homocysteine. In this comprehensive review, the authors discuss homocysteine metabolism and factors that influence plasma level of homocysteine. They illustrate that both environmental and genetic factors influence the plasma level of homocysteine. The authors also review the potential mechanisms by which elevated plasma level of homocysteine results in predisposition to atherosclerosis and thrombosis, and discuss the therapeutic options for patients with hyperhomocysteinemia.
65. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, et al.: Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation 1995, 92:2825-2830.
66. Stampfer MJ, Malinow R, Willett WC, Newcomer LM, Upson B, Ullmann D, et al.: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US Physicians. JAMA 1992, 268:877-881.
67. Mudd SH, Levy HL, Skovby F: Disorders of transsulfuration. In The Metabolic Basis of Inherited Disease. Edited by Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill; 1989:693-734
68. Goyette P, Summer JS, Milos R, Duncan AMV, Rosenblatt DS, Mathews RG, et al.: Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nature Genet 1994, 7:195-200.
69. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Mathews RG, et al.: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995, 10:111-113.
70. Goyette P, Frosst P, Rosenblatt DS, Rozen R: Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlation in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995, 56:1052-1059.
71. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al.: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996, 93:7-9.
72. Kluijtmans, LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, et al.: Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996, 58:35-41.
73. Brugada R, Marian AJ: A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis 1997, 128:107-112.
74. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, et al.: Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996, 94:2410-2416.
75. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J: Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction: a case-control study. Circulation 1996, 94:1812-1814.